Physician profile
Lee P Root
NPI 1700838760
$5,898.90
in general payments reported to CMS, 2019-2025
29 companies · $369 in 2025
The $369 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $963 · 2020: $862 · 2021: $876 · 2022: $1,206 · 2023: $953 · 2024: $671 · 2025: $369.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,993.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,992.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,745.03 | 2019-2025 | Lux-Dx Insertable Cardiac Monitor, Watchman Flx, Latitude Communicator Power Supply |
| Janssen Pharmaceuticals, INC | $639.27 | 2019-2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $406.46 | 2019-2024 | Camzyos, Eliquis |
| Edwards Lifesciences Corporation | $371.61 | 2019-2025 | Sapien 3 Ultra Resilia |
| Pfizer INC. | $347.70 | 2019-2023 | |
| Biotronik INC. | $298.31 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $240.70 | 2021-2023 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $237.25 | 2019-2023 | Farxiga |
| Novartis Pharmaceuticals Corporation | $235.45 | 2019-2024 | |
| Amgen INC. | $211.97 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $205.08 | 2021-2024 | Verquvo |
| Medtronic, INC. | $159.98 | 2025 | Symplicity G3 |
| Abbott Laboratories | $157.90 | 2019-2024 | Jot Dx |
| Bridgebio Pharma, INC. | $122.83 | 2025 | Attruby |
| Impulse Dynamics (USA) INC. | $112.64 | 2022-2023 | Optimizer |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $109.33 | 2019-2022 | |
| Kiniksa Pharmaceuticals, LTD. | $33.56 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $32.98 | 2019 | |
| Cvrx, INC. | $31.25 | 2023 | Barostim Neo System |
| Atricure, INC. | $29.42 | 2019 | |
| Sanofi-Aventis U.S. LLC | $28.04 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $27.05 | 2019 | |
| Medtronic Vascular, INC. | $21.06 | 2020 | |
| Arbor Pharmaceuticals, INC. | $18.28 | 2019 | |
| Gilead Sciences, INC. | $17.32 | 2019 | |
| Scpharmaceuticals INC. | $17.16 | 2025 | |
| Bardy Diagnostics, INC. | $14.96 | 2020 | |
| Preventice Services, LLC | $13.26 | 2021 | |
| Esperion Therapeutics, INC. | $13.05 | 2023 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lee Root listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.